Polizzotto MN; Nordwall J; Babiker AG; Phillips A; Vock DM; Eriobu N; Kwaghe V; Paredes R; Mateu L; Ramachandruni S; Narang R; Jain MK; Lazarte SM; Baker JV; Frosch AEP; Poulakou G; Syrigos KN; Arnoczy GS; McBride NA; Robinson PA; Sarafian F; Bhagani S; Taha HS; Benfield T; Liu STH; Antoniadou A; Jensen JUS; Kalomenidis I; Susilo A; Hariadi P; Jensen MD TO; Morales-Rull JL; Helleberg M; Meegada S; Johansen IS; Canario D; Fernández-Cruz E; Metallidis S; Shah A; Sakurai A; Koulouris NG; Trotman R; Weintrob AC; Podlekareva D; Hadi U; Lloyd KM; Røge BT; Saito S; Sweerus K; Malin JJ; Lübbert C; Muñoz J; Cummings MJ; Losso MH; Turner D; Shaw-Saliba K; Dewar R; Highbarger H; Lallemand P; Rehman T; Gerry N; Arlinda D; Chang CC; Grund B; Holbrook MR; Holley HP; Hudson F; McNay LA; Murray DD; Pett SL; Shaughnessy M; Smolskis MC; Touloumi G; Wright ME; Doyle MK; Popik S; Hall C; Ramanathan R; Cao H; Mondou E; Willis T; Thakuria JV; Yel L; Higgs E; Kan VL; Lundgren JD; Neaton JD; Lane HC, 2022, 'Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial',
The Lancet, vol. 399, pp. 530 - 540,
http://dx.doi.org/10.1016/S0140-6736(22)00101-5